6305-20-0

Basic information

• Product Name: (2-BROMOETHOXY)(PHENYL)METHYL]BENZENE
• Synonyms: ((2-broMoethoxy)Methylene)dibenzene;Benzene,1,1'-[(2-broMoethoxy)Methylene]bis-
• CAS NO: 6305-20-0
• Molecular Formula: C₁₅H₁₅BrO
• Molecular Weight: 291.183
• Mol File: 6305-20-0.mol
• Article Data: 12

Chemical Properties

• Appearance: /
• CAS DataBase Reference: (2-BROMOETHOXY)(PHENYL)METHYL]BENZENE(CAS DataBase Reference)
• NIST Chemistry Reference: (2-BROMOETHOXY)(PHENYL)METHYL]BENZENE(6305-20-0)
• EPA Substance Registry System: (2-BROMOETHOXY)(PHENYL)METHYL]BENZENE(6305-20-0)

Safety Data

• Hazardous Substances Data: 6305-20-0(Hazardous Substances Data)

Usage

General Description

The chemical compound (2-Bromoethoxy)(phenyl)methyl]benzene is a complex organic compound containing a benzene ring attached to a phenyl group through a bromoethoxy linkage. (2-BROMOETHOXY)(PHENYL)METHYL]BENZENE is a derivative of benzene and is used in the synthesis of various organic compounds. It possesses a phenyl group, which is a common functional group in organic chemistry, and a bromoethoxy group, which can be used as a leaving group in chemical reactions. (2-BROMOETHOXY)(PHENYL)METHYL]BENZENE is primarily utilized in the pharmaceutical and chemical industries for the synthesis of various drugs and organic compounds. Its specific properties and applications depend on the specific reactions and processes in which it is employed.

Upstream product

• 776-74-9 Bromodiphenylmethane 
• 540-51-2 2-bromoethanol 
• 579-55-5 fluorodiphenylmethane 
• 101-81-5 Diphenylmethane 
• 91-01-0 1,1-Diphenylmethanol 

Downstream Products

• 91573-65-8 (2-benzhydryloxy-ethyl)-propyl-amine 
• 102571-29-9 triethyl-(2-benzhydryloxy-ethyl)-ammonium; bromide 
• 150556-80-2 N,N'-dimethyl-N-[2-[bis(phenyl)methoxy]ethyl]-1,3-propanediamine 
• 258532-82-0 8-acetoxy-4-(2-(diphenylmethoxy)ethyl)-3-oxo-3,4-dihydro-2H-1,4-benzoxazine 
• 129084-17-9 1-[2-(diphenylmethoxy) ethyl]-3-(3-methoxyphenyl)pyrrolidine 
• 130210-11-6 2-diphenylmethoxyethanol nitrate 
• 17471-10-2 Desmethyldiphenhydramine 
• 1214734-01-6 1-(2-(benzhydryloxy)ethyl)-4-(4-chlorophenyl)piperidin-4-ol 
• 1059587-75-5 mPEG₆-N-diphenhydramine 
• 1059587-70-0 mPEG₃-N-diphenhydramine 
• 110283-70-0 1-<2-(diphenylmethoxy)ethyl>-3-piperidinecarboxylic acid 

Relevant articles and documents

Copper-Catalyzed C-H Fluorination/Functionalization Sequence Enabling Benzylic C-H Cross Coupling with Diverse Nucleophiles

Site-selective transformation of benzylic C-H bonds into diverse functional groups is achieved via Cu-catalyzed C-H fluorination with N-fluorobenzenesulfonimide (NFSI), followed by substitution of the resulting fluoride with various nucleophiles. The benzyl fluorides generated in these reactions are reactive electrophiles in the presence of hydrogen-bond donors or Lewis acids, allowing them to be used without isolation in C-O, C-N, and C-C coupling reactions.

Design, synthesis and pharmacological characterization of analogs of 2-aminoethyl diphenylborinate (2-APB), a known store-operated calcium channel blocker, for inhibition of TRPV6-mediated calcium transport

2-Aminoethyl diphenylborinate (2-APB) is a known modulator of the IP 3 receptor, the calcium ATPase SERCA, the calcium release-activated calcium channel Orai and TRP channels. More recently, it was shown that 2-APB is an efficient inhibitor of the epithelial calcium channel TRPV6 which is overexpressed in prostate cancer. We have conducted a structure-activity relationship study of 2-APB congeners to understand their inhibitory mode of action on TRPV6. Whereas modifying the aminoethyl moiety did not significantly change TRPV6 inhibition, substitution of the phenyl rings of 2-APB did. Our data show that the diaryl borinate moiety is required for biological activity and that the substitution pattern of the aryl rings can influence TRPV6 versus SOCE inhibition. We have also discovered that 2-APB is hydrolyzed and transesterified within minutes in solution.

OLIGOMER-ANTIHISTAMINE CONJUGATES

The invention provides antihistamine drugs that are chemically modified by covalent attachment of a water-soluble oligomer. A conjugate of the invention, when administered by any of a number of administration routes, exhibits characteristics that are different from the characteristics of the antihistamine drug not attached to the water-soluble oligomer.